[go: up one dir, main page]

WO2021246352A1 - Composition dermatologique externe pour une utilisation germicide et virucide - Google Patents

Composition dermatologique externe pour une utilisation germicide et virucide Download PDF

Info

Publication number
WO2021246352A1
WO2021246352A1 PCT/JP2021/020609 JP2021020609W WO2021246352A1 WO 2021246352 A1 WO2021246352 A1 WO 2021246352A1 JP 2021020609 W JP2021020609 W JP 2021020609W WO 2021246352 A1 WO2021246352 A1 WO 2021246352A1
Authority
WO
WIPO (PCT)
Prior art keywords
mass
less
acid
composition
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2021/020609
Other languages
English (en)
Japanese (ja)
Inventor
安弘 岡田
利哉 森川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Publication of WO2021246352A1 publication Critical patent/WO2021246352A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/362—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to an external skin preparation composition for sterilization or virus killing.
  • contact infection is the most common transmission route for bacteria or viruses in human daily life.
  • Contact infections are mainly caused by the contact of fingers with contact objects such as bacteria or virus infected persons, doorknobs, handles, tableware, toys, other daily necessities, and interior goods.
  • Patent Document 1 Japanese Patent Laid-Open No. 2008-523064
  • a compound or composition capable of reducing the skin pH to less than about 4 as a method for suppressing bacteria and viruses present on the skin surface of mammals.
  • methods comprising contacting the skin with the skin for at least about 0.5 hours.
  • Examples of the compound or composition capable of reducing the skin pH include those containing an organic acid such as a monocarboxylic acid or a polycarboxylic acid.
  • Patent Document 2 US Pat. No.
  • a virus-killing composition (hand lotion) containing citric acid, malic acid, and C1-6 alcohol is identified as having a rhinovirus cold.
  • a method of applying to the hands of a patient before exposure to rhinovirus to kill the rhinovirus and prevent the spread of the cold by the rhinovirus is disclosed.
  • the present invention provides the following [1] to [3].
  • [1] Other than (A) one or more acids selected from the group consisting of lactic acid, pyruvate and urocanic acid or salts thereof, and (B) component (A) having a pKa of 3.0 or more and 5.0 or less.
  • the content of the component (A) is 0.1% by mass or more and 10% by mass or less, and the content of the component (B) is 0.1% by mass or more and 10% by mass or less.
  • a method for protecting the skin from bacteria or viruses wherein one or more acids selected from the group consisting of (A) lactic acid, pyruvate and urocanic acid or salts thereof, and (B) pKa are 3. It contains an acid other than the component (A) which is 0 or more and 5.0 or less, or a salt thereof, and the content of the component (A) is 0.1% by mass or more and 10% by mass or less and the component (B).
  • a method comprising the step of applying a composition having a content of 0.1% by mass or more and 10% by mass or less and a pH of 3.5 or more and 5.0 or less to the skin.
  • component (A) having a pKa of 3.0 or more and 5.0 or less.
  • the content of the component (A) is 0.1% by mass or more and 10% by mass or less, and the content of the component (B) is 0.1% by mass or more and 10% by mass or less.
  • Example 3 is a graph showing pH changes on fingers to which Example 1, Comparative Example 1, Comparative Example 2, Comparative Example 3, and a control external finger composition are applied.
  • composition of external skin preparation for sterilization or virus killing The composition for external use of skin for sterilization or virus killing of the present invention (hereinafter, also referred to as “composition of the present invention") is used.
  • the composition of the present invention is an external skin preparation composition which is excellent in bactericidal or virus-killing effect and its sustainability, has less skin irritation, and is highly safe for the human body.
  • Patent Document 1 disclose compositions 2A to 2C containing citric acid and malic acid, of which the composition showing anti-rhinovirus activity has a composition pH of 2.3. Only thing 2A. Further, the pH of the anti-rhinovirus composition 2D containing citric acid and malic acid disclosed in Example 3 is 3.1. However, applying a low pH composition to the skin is not preferable from the viewpoint of skin irritation.
  • the hand lotion described in Patent Document 2 requires citric acid, malic acid, and C1-6 alcohol, and has not been shown to be virus-killing by hand lotions having other compositions.
  • An object of the present invention is to provide a composition for external skin for bactericidal or virus-killing, which has a good bactericidal or virus-killing effect and its sustainability, is less irritating to the skin, and is highly safe for the human body. ..
  • the present inventors have skin containing one or more acids selected from the group consisting of lactic acid, pyruvic acid and urocanic acid or salts thereof, and acids having a predetermined pKa or salts thereof, and having a predetermined pH range. It has been found that the external preparation composition can solve the above-mentioned problems.
  • a composition for external use of a skin for sterilization or virus-killing which has a good bactericidal or virus-killing effect and its sustainability, and has low skin irritation and high safety to the human body, and sterilization or killing. It is possible to provide a leave-on external preparation composition having a viral effect.
  • the term "bactericidal or virus-killing effect” refers to (1) a bactericidal / virus-killing effect expressed against bacteria / viruses adhering to the skin surface after the composition of the present invention is applied to the skin surface.
  • Bactericidal / virus-killing effect developed by applying the composition of the present invention to bacteria / viruses adhering to the skin (3) Effect of conditioning the skin to skin not mediated by bacteria / viruses, (4) ) The effect of protecting the skin from bacteria and viruses and keeping it hygienic, (5) the effect of preventing the transmission of bacteria and viruses through the skin and contact infection, and (6) the ability of the skin to protect against infection by bacteria and viruses. It includes concepts such as enhancing effect, and the composition of the present invention can be used in product forms such as hand disinfectants and hand cream cosmetics.
  • the term "persistence of bactericidal or virus-killing effect” means the ability to exhibit a bactericidal or virus-killing effect even after a long period of time after applying the composition of the present invention to the skin.
  • the bactericidal or virus-killing effect can be exhibited even after preferably 30 minutes or more, more preferably 60 minutes or more, and further preferably 120 minutes or more after applying the composition of the present invention to the skin.
  • the pH of the skin surface to which the composition is applied is maintained at a low pH, the bactericidal or virus-killing effect of the component (A) described later is enhanced, and more specifically, the composition is used. It is preferable that the ⁇ pH at 120 minutes after application is within 0.45.
  • the fungus or virus to which the composition of the present invention exerts a bactericidal or virus-killing effect is not particularly limited as long as it is inactivated or killed by contact with an acid, and is, for example, an infection in a nursery school of the Ministry of Health, Labor and Welfare. It is considered that the microorganisms described in the disease control guidelines can be applied.
  • the bacteria include anthrax, tuberculosis, hemolytic streptococcus, yellow staphylococcus, pneumoniae, etc., which are gram-positive bacteria, or Francisella tularensis, pest, brusella, and nasal bacillus, which are gram-negative bacteria.
  • the viruses include arenavirus, ebola virus, porosity virus, Nyrovirus, Marburg virus, coronavirus, monkey pox virus, beta coronavirus, influenza virus, RS virus, herpesvirus, mumps virus, and varicella.
  • the herpes zoster virus, wind shin virus, hemp virus and the like, and non-enveloped viruses entererovirus, adenovirus, coxsackie virus, norovirus, rotavirus and the like can be mentioned.
  • Escherichia coli, enterococci, and Serratia marcescens are taken as examples to evaluate the bactericidal property, which is attached to microorganisms that can be ethically attached to the skin or to human skin.
  • the evaluation method used is adopted from the viewpoint that it is a microorganism established in a public test method or an academic paper, and the fungus or virus targeted by the present invention is not limited thereto.
  • composition of the present invention exerts the above effect is not clear, but it is considered as follows.
  • Lactic acid, pyruvic acid, and urocanic acid which are components (A), originally exist on the surface of human skin by being supplied from sweat glands, and have a bactericidal and virus-killing function against bacteria, viruses, etc., especially on fingers.
  • the present inventors have found that they are responsible. Therefore, it is considered that the composition for external use on the skin containing the component (A) can be a composition having a bactericidal or virus-killing effect, less skin irritation, and high human safety.
  • lactic acid which is the component (A)
  • lactic acid can take the form of an acid type (CH 3 CH (OH) COOH) and a dissociated type (CH 3 CH (OH) COO ⁇ ) in an aqueous solution, but the acid type is more charged. It is considered that the acid type exhibits a higher bactericidal or virus-killing effect because it is easily taken up by bacteria or viruses.
  • the acid type / dissociation type ratio of lactic acid depends on the pH, and when the pH exceeds 5, the acid type presence ratio decreases, and the ratio of lactic acid present in the acid type to the total amount of lactic acid blended is, for example, 5. It will be below the mol% level.
  • the composition of the present invention exhibits a good bactericidal or virus-killing effect against bacteria or viruses when the pH is 5.0 or less.
  • the present inventors have a pH in a relatively high range of 3.5 or more by using a predetermined amount of each of the component (A) and the component (B) which is an acid having a predetermined pKa or a salt thereof.
  • the component (B) is a weak acid or a salt thereof and has a buffering action
  • the composition used in combination with the component (A) suppresses the increase in pH over time even after the composition is applied to the skin.
  • the ratio of the acid-type component (A), which is the main bactericidal or virus-killing component is kept in a high range, so that the bactericidal or virus-killing effect is considered to be sustained for a long time.
  • the composition of the present invention is preferably a leave-on preparation. This is because the composition of the present invention can improve the bactericidal or virus-killing effect on bacteria or viruses and the sustainability thereof by leaving the component (A) which is a bactericidal or virus-killing component on the skin surface. Therefore, it is preferable that the composition of the present invention is applied to the skin and then left on the skin surface without being removed by washing with water or the like. Further, from the viewpoint of preventing contact infection by bacteria or viruses, it is more preferable to apply it to fingers even on the surface of the skin.
  • the component (A) used in the composition of the present invention is one or more acids selected from the group consisting of lactic acid, pyruvic acid and urocanic acid, or salts thereof.
  • Component (A) acts as a bactericidal or virus-killing component.
  • the salts of lactic acid, pyruvate and urocanic acid include alkali metal salts of lactic acid or pyruvate such as potassium salt and sodium salt; alkaline earth metal salts such as calcium salt and magnesium salt; amine salts; ammonium salts and the like. Be done.
  • alkali metal salts and alkaline earth metal salts of lactic acid, pyruvate and urocanic acid from the viewpoint of bactericidal or virus-killing effect and its sustainability improvement, and from the viewpoint of availability. More than one species is preferable, one or more selected from the group consisting of potassium salt, sodium salt, and calcium salt is more preferable, and one or more species selected from the group consisting of potassium lactate, sodium lactate, and calcium lactate is further preferable.
  • lactic acid or a salt thereof is preferable as the component (A), and one or more selected from the group consisting of lactic acid, potassium lactate, sodium lactate, and calcium lactate is more preferable. , Lactic acid is more preferable. Further, the content of lactic acid or a salt thereof in the total amount of the component (A) is preferably 80% by mass or more, more preferably 90% by mass or more, from the viewpoint of bactericidal or virus-killing effect and improvement of its sustainability. Yes, most preferably 100% by mass.
  • the content of the component (A) in the composition of the present invention is 0.1% by mass or more, preferably 0.3% by mass or more, more preferably 0.3% by mass or more, from the viewpoint of bactericidal or virus-killing effect and improvement of its sustainability. Is 0.5% by mass or more, more preferably 0.8% by mass or more. Further, from the viewpoint of suppressing skin irritation, it is 10% by mass or less, preferably 8.0% by mass or less, more preferably 6.0% by mass or less, still more preferably 5.0% by mass or less, still more preferably. Is 3.0% by mass or less, more preferably 1.5% by mass or less.
  • the content of the component (A) in the composition of the present invention is 0.1% by mass or more and 10% by mass or less, preferably 0.3% by mass or more and 8.0% by mass or less, and more preferably 0. .3% by mass or more and 6.0% by mass or less, more preferably 0.3% by mass or more and 5.0% by mass or less, still more preferably 0.3% by mass or more and 3.0% by mass or less, still more preferably 0. .3% by mass or more and 1.5% by mass or less, more preferably 0.5% by mass or more and 1.5% by mass or less.
  • the "content of the component (A)" means an amount converted into an acid.
  • the content of the component (A) present in the acid form in the composition of the present invention is preferably 0.01% by mass or more, more preferably 0. It is 1% by mass or more, more preferably 0.2% by mass or more, and even more preferably 0.3% by mass or more. Further, from the viewpoint of suppressing skin irritation, it is preferably 7% by mass or less, more preferably 3.5% by mass or less, still more preferably 2.5% by mass or less, still more preferably 2% by mass or less, still more preferably. Is 1.5% by mass or less, more preferably 1% by mass or less.
  • the content of the component (A) present in the acid form in the composition of the present invention is preferably 0.01% by mass or more and 7% by mass or less, more preferably 0.1% by mass or more and 3.5% by mass. % Or less, more preferably 0.1% by mass or more and 2.5% by mass or less, still more preferably 0.1% by mass or more and 2% by mass or less, still more preferably 0.1% by mass or more and 1.5% by mass or less. , More preferably 0.1% by mass or more and 1% by mass or less, still more preferably 0.2% by mass or more and 1% by mass or less, and even more preferably 0.3% by mass or more and 1% by mass or less.
  • the molar ratio of the component (A) present in the acid type to the total of the component (A) present in the acid type and the component (A) present in the dissociated type in the composition of the present invention [acid type / (acid type). + Dissociation type)] is preferably 0.068 or more, more preferably 0.12 or more, from the viewpoint of bactericidal or virus-killing effect and its sustainability improvement. Further, from the viewpoint of suppressing skin irritation, it is preferably 0.7 or less, more preferably 0.5 or less.
  • the molar ratio [acid type / (acid type + dissociation type)] in the composition is preferably 0.068 or more and 0.7 or less, and more preferably 0.12 or more and 0.5 or less. Specifically, the molar ratio can be calculated by the method described in Examples.
  • the component (A) which exists in an acid form in a composition means the component (A) which exists as lactic acid, pyruvic acid and urocanic acid in a composition.
  • “Dissociated component (A) in the composition” means a component of the component (A) that is present as lactic acid ion, pyruvate ion and urocanate ion in the composition.
  • the component (B) used in the composition of the present invention is an acid other than the component (A) having a pKa of 3.0 or more and 5.0 or less, or a salt thereof.
  • the composition of the present invention exerts a buffering action by containing the component (A) and the component (B), and even after applying the composition having a pH in a relatively high range of 3.5 or more to the skin, the skin It is considered that the increase in pH of the surface over time can be suppressed. As a result, it is considered that the decrease in the ratio of the acid type component (A) on the skin surface is suppressed, and the bactericidal or virus-killing effect can be sustained for a long time.
  • pKa means the acid dissociation constant in an aqueous solution at 25 ° C.
  • acids having a plurality of pKa such as the first acid dissociation constant (PKa 1 ) and the second acid dissociation constant (PKa 2 )
  • any acid having a pKa of 3.0 or more and 5.0 or less is required.
  • the acid in the component (B) has a pKa of 3 as the acid in the component (B) from the viewpoint of improving the bactericidal or virus-killing effect of the skin surface to which the composition is applied and its persistence, and suppressing the skin irritation. It is 9.0 or more, preferably 3.2 or more, more preferably 3.5 or more, still more preferably 3.7 or more, still more preferably 4.0 or more. Further, from the viewpoint of exerting a buffering action when used in combination with the component (A), the pKa is 5.0 or less, preferably 4.7 or less, and more preferably 4.5 or less.
  • the pKa of the acid in the component (B) is 3.0 or more and 5.0 or less, preferably 3.2 or more and 4.7 or less, more preferably 3.5 or more and 4.5 or less, and further preferably 3. It is 7.7 or more and 4.5 or less, more preferably 4.0 or more and 4.5 or less.
  • the pKa having a larger value keeps the pH of the composition at 5.0 or less. , It is considered that it contributes to the bactericidal or virus-killing effect of the skin surface to which the composition is applied and the effect of improving its sustainability.
  • the acid in the component (B) may be either an organic acid or an inorganic acid as long as it has the above pKa, but an organic acid is preferable from the viewpoint of suppressing skin irritation.
  • the organic acid may be a monovalent acid or a polyvalent acid, but is preferably a polyvalent acid from the viewpoint of improving the sustainability of the bactericidal or virus-killing effect on the skin surface to which the composition is applied.
  • As the organic acid ascorbic acid and a carboxylic acid compound are preferable. These may be either low molecular weight compounds or high molecular weight compounds, but from the viewpoint of water solubility, they are preferably low molecular weight compounds having 8 or less carbon atoms, and more preferably 6 or less carbon atoms.
  • the acid in the component (B) include ascorbic acid (primary acid dissociation constant pKa 1 : 4.17, secondary acid dissociation constant pKa 2 : 11.6, molecular weight 176.1 g / mol); gluconic acid ( Acid dissociation constant pKa: 3.86, molecular weight 196 g / mol), citric acid (primary acid dissociation constant pKa 1 : 3.09, secondary acid dissociation constant pKa 2 : 4.8, tertiary acid dissociation constant pKa 3 : 6.41, molecular weight 192.1 g / mol (anhydrous)), malic acid (primary acid dissociation constant pKa 1 : 3.4, secondary acid dissociation constant pKa 2 : 5.1, molecular weight 134.1 g / mol) , Tartrate (first acid dissociation constant pKa 1 : 2.82, second acid dissociation constant pKa 2 : 3.
  • the molecular weight of the acid in the component (B) is preferably 50 g / mol or more, more preferably 80 g / mol or more, from the viewpoint of improving the sustainability of the bactericidal or virus-killing effect. Further, from the viewpoint of improving the bactericidal or virus-killing effect, it is preferably 300 g / mol or less, and more preferably 150 g / mol or less.
  • the molecular weight of the acid in the component (B) is preferably 50 g / mol or more and 300 g / mol or less, and more preferably 80 g / mol or more and 150 g / mol or less.
  • Examples of the acid salt in the component (B) include alkali metal salts such as potassium salt and sodium salt of the acid; alkaline earth metal salts such as calcium salt and magnesium salt; amine salt; ammonium salt and the like.
  • alkali metal salts such as potassium salt and sodium salt of the acid
  • alkaline earth metal salts such as calcium salt and magnesium salt
  • amine salt such as calcium salt and magnesium salt
  • ammonium salt and the like examples of the acid salt in the component (B) include alkali metal salts such as potassium salt and sodium salt of the acid; alkaline earth metal salts such as calcium salt and magnesium salt; amine salt; ammonium salt and the like.
  • alkali metal salts such as potassium salt and sodium salt of the acid
  • alkaline earth metal salts such as calcium salt and magnesium salt
  • amine salt such as calcium salt and magnesium salt
  • ammonium salt and the like ammonium salt and the like.
  • the component (B) is one selected from the group consisting of ascorbic acid, hydroxycarboxylic acid, polyvalent carboxylic acid having no hydroxy group, and salts thereof.
  • the above is preferable, a polyvalent carboxylic acid having no hydroxy group or a salt thereof is more preferable, a polyvalent carboxylic acid having no hydroxy group is more preferable, and one or more selected from the group consisting of succinic acid and adipic acid is preferable. Even more preferred, succinic acid is even more preferred.
  • the content of the component (B) in the composition of the present invention is 0.1% by mass or more, preferably 0.3% by mass or more, more preferably 0.3% by mass or more, from the viewpoint of bactericidal or virus-killing effect and improvement of its sustainability. Is 0.5% by mass or more, more preferably 0.7% by mass or more. Further, from the viewpoint of suppressing skin irritation, it is 10% by mass or less, preferably 7% by mass or less, further preferably 5% by mass or less, still more preferably 3% by mass or less.
  • the content of the component (B) in the composition of the present invention is 0.1% by mass or more and 10% by mass or less, preferably 0.3% by mass or more and 7% by mass or less, more preferably 0.5.
  • the component (B) contains a salt
  • the "content of the component (B)" means an amount converted into an acid
  • the total content of the component (A) and the component (B) in the composition of the present invention is preferably 0.2% by mass or more, more preferably 0. 3% by mass or more, still more preferably 0.5% by mass or more, still more preferably 0.8% by mass or more, still more preferably 1% by mass or more, still more preferably 1.2% by mass or more, still more preferably. It is 1.5% by mass or more, more preferably 1.7% by mass or more. Further, from the viewpoint of suppressing skin irritation, it is preferably 15% by mass or less, more preferably 10% by mass or less, still more preferably 8% by mass or less, still more preferably 6% by mass or less, still more preferably 5% by mass. % Or less, more preferably 3% by mass or less.
  • the specific range of the total content of the component (A) and the component (B) in the composition of the present invention is preferably 0.2% by mass or more and 15% by mass or less, more preferably 0.3% by mass or more. 10% by mass or less, more preferably 0.5% by mass or more and 8% by mass or less, still more preferably 0.8% by mass or more and 6% by mass or less, still more preferably 1% by mass or more and 6% by mass or less, still more preferable. Is 1.2% by mass or more and 6% by mass or less, more preferably 1.5% by mass or more and 5% by mass or less, still more preferably 1.7% by mass or more and 5% by mass or less, still more preferably 1.7% by mass. % Or more and 3% by mass or less.
  • the mass ratio (B / A) of the component (B) to the component (A) in the composition of the present invention is preferably 0.1 or more, more preferably 0.1 or more, from the viewpoint of improving the sustainability of the bactericidal or virus-killing effect. Is 0.2 or more, more preferably 0.5 or more. Further, from the viewpoint of improving the bactericidal or virus-killing effect, it is preferably 20 or less, more preferably 10 or less, still more preferably 8 or less, still more preferably 7 or less, still more preferably 6 or less, still more preferably 5 or less. be.
  • the mass ratio (B / A) in the composition of the present invention is preferably 0.1 or more and 20 or less, more preferably 0.2 or more and 10 or less, still more preferably 0.2 or more and 8 or less, and further. It is preferably 0.2 or more and 7 or less, more preferably 0.2 or more and 6 or less, still more preferably 0.2 or more and 5 or less, and even more preferably 0.5 or more and 5 or less.
  • the composition of the present invention preferably further contains water from the viewpoint of dissolving the component (A) and the component (B) and facilitating application to the skin surface.
  • the content of water in the composition of the present invention is preferably 10% by mass or more, more preferably 30% by mass or more, still more preferably 50% by mass or more, still more preferably 70% by mass or more, and more preferably. Is 99.8% by mass or less, more preferably 99% by mass or less.
  • the content of water in the composition of the present invention is preferably 10% by mass or more and 99.8% by mass or less, more preferably 30% by mass or more and 99.8% by mass or less, and further preferably 50% by mass or more and 99. It is 8.8% by mass or less, more preferably 70% by mass or more and 99% by mass or less.
  • the composition of the present invention preferably limits the content of clay minerals used for adsorbing and removing oil components and proteins.
  • the clay minerals include silt; marine silt; tanakura clay; bentnite, montmorillonite, herculite, byderite, nontonite, saponite, hectrite, lucentite, soconite and stibunchite smectite clay minerals; kaolin, nacrite, deckite, halloysite.
  • kaolin-based clay minerals such as chrysotile; antigolite-based clay minerals such as antigolite, amesite and cronsteadite; pyrophyllite-based clay minerals such as pyrophyllite and talc (talc); , Celadonite, sericite, mica (mica), white mica, chrome white mica, black mica and other mica clay minerals; vermiculite clay minerals such as vermiculite; and green mudstone (chlorite) and other green mudstone clay minerals. Can be mentioned.
  • limiting the content of clay mineral means that the content of clay mineral in the composition of the present invention is preferably 3% by mass or less, more preferably 1% by mass or less, and further preferably substantially contained. Means not.
  • the total content of the component (A), the component (B) and water in the composition of the present invention is preferably 50% by mass or more, more preferably 70% by mass or more, still more preferably, from the viewpoint of obtaining the effect of the present invention. Is 80% by mass or more, more preferably 90% by mass or more, still more preferably 95% by mass or more, and 100% by mass or less.
  • the composition of the present invention may contain other components, for example, acids other than the components (A) and (B) or salts thereof, surfactants, thickeners, pH adjusters, as necessary. It can also contain an ultraviolet absorber, an antioxidant, an antiseptic, an antiperspirant, a fragrance, a moisturizer and the like.
  • a surfactant in the composition of the present invention.
  • Surfactants include nonionic surfactants, anionic surfactants, cationic surfactants (excluding quaternary ammonium salts), amphoteric surfactants (excluding alkyldiaminoethylglycine hydrochloride and alkylpolyaminoethylglycine). ) Etc. can be mentioned. Among these, one or more selected from the group consisting of nonionic surfactants and anionic surfactants is preferable from the viewpoint of further improving the bactericidal or virus-killing effect and its sustainability.
  • nonionic surfactant examples include alkyl glucoside, sucrose fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene fatty acid ester, polyglycerin fatty acid ester, and polyethylene glycol fatty acid ester from the viewpoint of improving the bactericidal or virus-killing effect. And one or more selected from the group consisting of polyoxyethylene alkyl ethers are preferred.
  • the average number of moles of ethyleneoxy groups added in polyoxyethylene sorbitan fatty acid ester, polyoxyethylene fatty acid ester, polyglycerin fatty acid ester, polyethylene glycol fatty acid ester, and polyoxyethylene alkyl ether (hereinafter referred to as "EO average number of added moles"). ) Is more preferably 3 or more and 20 or less, further preferably 3 or more and 15 or less, further preferably 5 or more and 9 or less, and further preferably 5 or more and 8 or less.
  • the EO average number of moles added is a number average value.
  • polyoxyethylene alkyl ether is more preferable as the nonionic surfactant.
  • a polyoxyethylene alkyl ether having 8 or more and 20 or less alkyl groups constituting the polyoxyethylene alkyl ether is preferable, and the EO average number of moles of the polyoxyethylene alkyl ether is 3. It is more preferably 20 or less, further preferably 3 or more and 15 or less, further preferably 5 or more and 9 or less, and even more preferably 5 or more and 8 or less.
  • the HLB value is preferably 8 or more and 16 or less, more preferably 10 or more and 14 or less, and further preferably 10 or more and 13 or less, from the viewpoint of improving the bactericidal or virus-killing effect.
  • HLB Hydrophilic-Lipophilic Balance
  • the HLB of a mixed surfactant composed of two or more types of nonionic surfactants is a phase-added average of the HLB values of each nonionic surfactant based on the blending ratio, and is as follows. Desired.
  • HLB ⁇ (HLBx ⁇ Wx) / ⁇ Wx HLBx indicates the HLB value of the nonionic surfactant X.
  • Wx indicates the mass (g) of the nonionic surfactant X having a value of HLBx.
  • the anionic surfactant comprises an alkyl sulfate ester salt, an alkyl phosphate ester salt, a polyoxyethylene alkyl ether sulfate ester salt, and a polyoxyethylene alkyl ether phosphate salt from the viewpoint of improving the bactericidal or virus-killing effect.
  • One or more selected from the group is preferable.
  • the content of the surfactant in the composition of the present invention is preferably 0.01% by mass or more, more preferably 0. It is 05% by mass or more, more preferably 0.1% by mass or more, still more preferably 0.3% by mass or more, and preferably 10% by mass or less, more preferably 5 from the viewpoint of suppressing skin irritation. It is mass% or less, more preferably 3% by mass or less, still more preferably 2% by mass or less.
  • the specific range of the content of the surfactant in the composition of the present invention is preferably 0.01% by mass or more and 10% by mass or less, more preferably 0.05% by mass or more and 5% by mass or less, and further preferably 0. .1% by mass or more and 3% by mass or less, more preferably 0.3% by mass or more and 2% by mass or less.
  • the composition of the present invention can be used as a sterilizing or virus-killing composition even if the ethanol content is low, from the viewpoint that the composition uses the component (A) as a sterilizing or virus-killing component.
  • the content of ethanol in the composition is preferably 70% by mass or less, more preferably 50% by mass or less, still more preferably 30% by mass or less, still more preferably. Is 10% by mass or less, and more preferably 0% by mass.
  • composition of the present invention is a quaternary ammonium salt such as benzalkonium chloride and benzethonium chloride from the viewpoint of using the component (A) as a bactericidal or virus-killing component; alkyldiaminoethylglycine hydrochloride, alkylpolyamino.
  • Amphoteric surfactant-based disinfectants such as ethylglycine; biguanides such as chlorhexidine and chlorhexidine gluconate; sodium hypochlorite; lower alcohols other than ethanol such as isopropanol; aldehydes such as glutaral, phthalal and formarin; iodotinki; It can be used as a bactericidal or virus-killing composition without or in a small amount of a general-purpose disinfectant such as phenol; chlorhexidine solution; peracetic acid; oxidol; When a general-purpose bactericidal agent is blended in the composition, benzalkonium chloride is used from the viewpoint of maintaining the skin pH in a low range by the component (A) and the component (B), thereby enhancing the bactericidal sustaining effect of the general-purpose bactericidal agent.
  • a general-purpose bactericidal agent is blended in the composition, benzalkonium chloride is used from the viewpoint
  • the blending amount is preferably 0.01% by mass or more, more preferably 0.03% by mass or more, still more preferably, from the viewpoint of sterilizing or virus-killing effect and improving its sustainability. Is 0.05% by mass or more. On the other hand, from the viewpoint of suppressing skin irritation, it is preferably 15% by mass or less, more preferably 10% by mass or less, still more preferably 5% by mass or less, still more preferably 3% by mass or less, still more preferably 1% by mass.
  • the above-mentioned general-purpose fungicide and also acting as a surfactant is defined as a general-purpose fungicide.
  • the composition of the present invention preferably has a low content of polyol from the viewpoint of improving usability.
  • the polyol referred to here refers to a compound other than the component (A) and the component (B) having two or more hydroxy groups in the molecule.
  • the content of the polyol in the composition is preferably 20% by mass or less, more preferably 10% by mass or less, still more preferably 5% by mass or less, still more preferably 3% by mass or less, from the viewpoint of improving the usability. , More preferably, it is substantially 0% by mass.
  • the ratio of the total content of ethanol, isopropanol, and polyol to the content of water in the composition of the present invention is a mass ratio [(ethanol +) from the viewpoint of suppressing skin irritation and improving usability.
  • Isopropanol + polyol) / water] is preferably 2 or less, more preferably 1 or less, still more preferably 0.5 or less, still more preferably 0.1 or less.
  • the composition of the present invention has a pH of 3.5 or higher, preferably 3.7 or higher, from the viewpoint of suppressing skin irritation. Further, from the viewpoint of bactericidal or virus-killing effect and improvement of its sustainability, it is 5.0 or less, preferably 4.5 or less.
  • the specific pH range of the composition of the present invention is 3.5 or more and 5.0 or less, preferably 3.7 or more and 4.5 or less.
  • the pH is a value at 25 ° C., and can be specifically measured by the method described in Examples.
  • the form of the composition of the present invention is not particularly limited, and may be, for example, solid, liquid, gel, or cream. From the viewpoint of ease of application to the skin, it is preferably in the form of a gel or cream.
  • the composition may be in the form of an emulsified composition, and the emulsified composition may be either an oil-in-water emulsified composition or a water-in-oil emulsified composition.
  • the composition of the present invention is preferably used as a leave-on preparation, but the dosage form of the preparation is not particularly limited.
  • a stick preparation provided with a solid composition; a roll-on preparation filled with a liquid composition.
  • a spray formulation a formulation in which a liquid, gel-like or cream-like composition is filled in a bottle, tube, dispenser-type container or the like, a sheet product impregnated with the composition, or the like can be mentioned.
  • Examples of the product form of the composition of the present invention include lotions, gels, sprays, creams, etc. for fingers or bodies.
  • the present invention is also a method of protecting the skin from bacteria or viruses.
  • A One or more acids selected from the group consisting of lactic acid, pyruvic acid and urocanic acid or salts thereof, and
  • B An acid other than the component (A) having a pKa of 3.0 or more and 5.0 or less, or a salt thereof,
  • the content of the component (A) is 0.1% by mass or more and 10% by mass or less
  • the content of the component (B) is 0.1% by mass or more and 10% by mass or less
  • the pH is 3.
  • a method having a step of applying a composition of 5 or more and 5.0 or less to the skin hereinafter, also simply referred to as “the method of the present invention”.
  • the skin is protected from bacteria or viruses by the bactericidal or virus-killing effect and its persistence, and the skin irritation is low, so that the safety to the human body is high.
  • composition of the present invention described above is preferable as the composition used in the method of the present invention, and the details and suitable range thereof are the same as those of the composition.
  • the fungus or virus to be protected by the method of the present invention is the same as described above.
  • the method for applying the composition to the skin can be appropriately selected depending on the dosage form, application site, etc. of the composition, and for example, the composition can be applied to the skin by application, spraying, or the like.
  • the body part to which the composition is applied is not particularly limited, and can be applied to any body part such as fingers, upper arms, lower limbs, neck, and torso. From the viewpoint of cutting off the route of infection and transmission of bacteria and viruses by contact between humans and objects, it is preferable to apply it to public objects and fingers that often touch the nose and mouth of oneself in daily life.
  • the amount of component (A) present in the acid form in the skin surface to which the said composition improves skin 1 cm 2 per preferably 0. It is 2 ⁇ g or more, more preferably 1.5 ⁇ g or more, still more preferably 1.7 ⁇ g or more, still more preferably 1.8 ⁇ g or more, still more preferably 2 ⁇ g or more. Further, from the viewpoint of suppressing skin irritation, it is preferably 200 ⁇ g or less, more preferably 100 ⁇ g or less, and further preferably 50 ⁇ g or less.
  • the amount of component (A) in the skin surface to which the said composition, present in acid form, preferably per skin 1 cm 2 is 0.2 ⁇ g least 200 ⁇ g or less, more preferably 1.5 ⁇ g least 200 ⁇ g or less, more preferably Is 1.7 ⁇ g or more and 100 ⁇ g or less, more preferably 1.8 ⁇ g or more and 50 ⁇ g or less, and even more preferably 2 ⁇ g or more and 50 ⁇ g or less.
  • the "amount of the acid-type component (A) present on the skin surface to which the composition is applied” is the acid-type component derived from the composition on the skin surface at the time of applying the composition (the composition). It is the total amount of A) and the acid-type component (A) naturally present on the skin surface, and can be specifically obtained by the method described in Examples.
  • the molar ratio of the component (A) present in the acid type to the total of the component (A) present in the acid type and the component (A) present in the dissociated type on the skin surface to which the composition is applied is preferably 0.15 or more, more preferably 0.17 or more, still more preferably 0.18 or more, from the viewpoint of bactericidal or virus-killing effect and its sustainability improvement. Further, from the viewpoint of suppressing skin irritation, it is preferably 0.70 or less, more preferably 0.50 or less, still more preferably 0.30 or less.
  • the molar ratio [acid type / (acid type + dissociation type)] on the skin surface to which the composition is applied is preferably 0.15 or more and 0.70 or less, more preferably 0.17 or more and 0.50 or less. , More preferably 0.18 or more and 0.30 or less.
  • the component (A) derived from the composition on the skin surface at the time of applying the composition and the component naturally present on the skin surface ( Both A) are considered.
  • the molar ratio can be specifically determined by the method described in Examples.
  • the pH of the skin surface after applying the composition is preferably 3.50 or higher, more preferably 3.70 or higher, still more preferably 3.90 or higher, from the viewpoint of suppressing skin irritation. Further, from the viewpoint of bactericidal or virus-killing effect and improvement of its sustainability, the pH of the skin surface after applying the composition is preferably 4.60 or less, more preferably 4.55 or less, still more preferably 4.50. It is as follows. The pH of the skin surface after applying the composition is preferably 3.50 or more and 4.60 or less, more preferably 3.70 or more and 4.55 or less, and further preferably 3.90 or more and 4.50 or less. Is.
  • the pH of the skin surface is preferably in the above range even after 30 minutes or more, more preferably 60 minutes or more after applying the composition.
  • the pH of the skin surface is a measured value at an environmental temperature to which the method of the present invention is applied, and can be specifically measured by the method described in Examples.
  • the composition is not removed by washing with water or the like after being applied to the skin, but remains on the skin surface.
  • the composition can be used as a leave-on preparation to leave the component (A), which is a bactericidal or virus-killing component, on the skin surface, thereby imparting a bactericidal or virus-killing effect and its persistence.
  • the composition may be applied to the skin after washing the skin with water, soap, body soap, hand soap or the like in advance, or may be applied to the unwashed skin.
  • the washed skin is in a state in which components such as lactic acid that are naturally present are washed away and the bactericidal or virus-killing property against bacteria and viruses existing in the outside world is reduced. It is more preferable to apply a substance to carry out the method of the present invention.
  • the present invention is also a leave-on finger external preparation composition.
  • A One or more acids selected from the group consisting of lactic acid, pyruvic acid and urocanic acid or salts thereof, and
  • B An acid other than the component (A) having a pKa of 3.0 or more and 5.0 or less, or a salt thereof,
  • the content of the component (A) is 0.1% by mass or more and 10% by mass or less
  • the content of the component (B) is 0.1% by mass or more and 10% by mass or less
  • the pH is 3. 5 or more and 5.0 or less
  • Provided is a leave-on finger external preparation composition having a clay mineral content of 3% by mass or less.
  • the leave-on finger external preparation composition of the present invention has a high bactericidal or virus-killing effect and its durability, and has low skin irritation, so that it is highly safe for the human body.
  • the components (A) and (B) used in the leave-on finger external preparation composition, the clay minerals specified in the leave-on finger external preparation composition, and the details and suitable ranges thereof are the same as those of the composition of the present invention.
  • the composition of the present invention is described below from the viewpoint of providing a bactericidal or virus-killing external preparation composition for bactericidal or virus-killing, which has a high bactericidal or virus-killing effect and its durability, is less irritating to the skin, and is highly safe for the human body.
  • It contains the component (A) and the component (B), the content of the component (A) is 0.1% by mass or more and 1.5% by mass or less, and the content of the component (B) is 0.3% by mass or more.
  • It is preferably a composition for external use of fingers for sterilization or virus killing, which is 10% by mass or less and has a pH of 3.5 or more and 5.0 or less.
  • the composition of the present invention has the following components (A) and the following components (A) from the viewpoint of providing a leave-on hand-finger external preparation composition having a bactericidal or virus-killing effect, high durability thereof, low skin irritation, and high safety to the human body.
  • the content of the component (B) is contained, the content of the component (A) is 0.1% by mass or more and 1.5% by mass or less, and the content of the component (B) is 0.3% by mass or more and 10% by mass or less.
  • the composition is a leave-on external preparation for fingers having a pH of 3.5 or more and 5.0 or less.
  • Lactic acid or a salt thereof (B) An acid other than the component (A) having a pKa of 3.5 or more and 4.5 or less, or a salt thereof.
  • the present invention further discloses the following embodiments.
  • ⁇ 1> (A) One or more acids selected from the group consisting of lactic acid, pyruvic acid and urocanic acid or salts thereof, and (B) An acid other than the component (A) having a pKa of 3.0 or more and 5.0 or less, or a salt thereof, Contains, The content of the component (A) is 0.1% by mass or more and 10% by mass or less. The content of the component (B) is 0.1% by mass or more and 10% by mass or less.
  • An external skin composition for sterilization or virus killing, wherein the pH at 25 ° C. is 3.5 or more and 5.0 or less.
  • the content of the component (A) in the external preparation composition for skin is preferably 0.3% by mass or more and 8.0% by mass or less, more preferably 0.3% by mass or more and 6.0% by mass or less, still more preferably. Is 0.3% by mass or more and 5.0% by mass or less, more preferably 0.3% by mass or more and 3.0% by mass or less, still more preferably 0.3% by mass or more and 1.5% by mass or less, still more.
  • the composition for external skin preparation for sterilization or virus killing of ⁇ 1> preferably 0.5% by mass or more and 1.5% by mass or less.
  • the content of the component (A) present in the acid form in the external preparation composition for skin is preferably 0.01% by mass or more and 7% by mass or less, more preferably 0.1% by mass or more and 3.5% by mass.
  • an external skin preparation composition for sterilizing or killing virus according to ⁇ 2> is preferably 0.1% by mass or more and 7% by mass or less, more preferably 0.1% by mass or more and 3.5% by mass.
  • more preferably 0.1% by mass or more and 2.5% by mass or less still more preferably 0.1% by mass or more and 2% by mass or less, still more
  • the pKa of the acid in the component (B) is preferably 3.2 or more and 4.7 or less, more preferably 3.5 or more and 4.5 or less, still more preferably 3.7 or more and 4.5 or less, still more preferably 4. .0 or more and 4.5 or less, the composition for external skin preparation for sterilization or virus killing of any one of ⁇ 1> to ⁇ 3>.
  • the acid in the component (B) is at least one selected from the group consisting of ascorbic acid, gluconic acid, citric acid, malic acid, tartaric acid, fumaric acid, succinic acid, adipic acid, and polyacrylic acid, ⁇ 1>.
  • ⁇ ⁇ 4> The composition for external skin preparation for sterilizing or killing a virus according to any one of ⁇ 4>.
  • a composition for external use of skin for virus killing ⁇ 7>
  • the content of the component (B) in the external preparation composition for skin is preferably 0.3% by mass or more and 7% by mass or less, more preferably 0.5% by mass or more and 5% by mass or less, still more preferably 0.7.
  • the composition for external skin preparation for sterilization or virus killing according to any one of ⁇ 1> to ⁇ 6>, which is 5% by mass or more, more preferably 0.7% by mass or more and 3% by mass or less.
  • the mass ratio (B / A) of the component (B) to the component (A) in the external preparation composition for skin is preferably 0.1 or more and 20 or less, more preferably 0.2 or more and 10 or less, and further preferably 0. .2 or more and 8 or less, more preferably 0.2 or more and 7 or less, still more preferably 0.2 or more and 6 or less, still more preferably 0.2 or more and 5 or less, still more preferably 0.5 or more and 5 or less.
  • the external preparation composition for skin further contains water, and the content of water in the composition is preferably 10% by mass or more and 99.8% by mass or less, more preferably 30% by mass or more and 99.8% by mass or less. , More preferably 50% by mass or more and 99.8% by mass or less, still more preferably 70% by mass or more and 99% by mass or less, for external use on the skin for sterilization or virus killing of any one of ⁇ 1> to ⁇ 8>.
  • Agent composition is preferably 50% by mass or more and 99.8% by mass or less, still more preferably 70% by mass or more and 99% by mass or less, for external use on the skin for sterilization or virus killing of any one of ⁇ 1> to ⁇ 8>.
  • the content of the clay mineral in the external skin preparation composition is preferably 3% by mass or less, more preferably 1% by mass or less, and further preferably substantially not contained, any of ⁇ 1> to ⁇ 9>.
  • the content of the general-purpose bactericidal agent in the external preparation composition for skin is preferably 15% by mass or less, more preferably 10% by mass or less, still more preferably 5% by mass or less, still more preferably 3% by mass or less, still more.
  • ⁇ 1> to ⁇ 10> preferably 1% by mass or less, still more preferably 0.07% by mass or less, still more preferably 0.03% by mass or less, and substantially 0% by mass.
  • ⁇ 12> The skin external preparation composition for sterilization or virus killing according to any one of ⁇ 1> to ⁇ 11>, wherein the pH of the external skin preparation composition at 25 ° C. is preferably 3.7 or more and 4.5 or less.
  • ⁇ 13> Any of ⁇ 1> to ⁇ 12>, wherein the content of lactic acid or a salt thereof in the total amount of the component (A) is preferably 80% by mass or more, more preferably 90% by mass or more, and most preferably 100% by mass. 1.
  • surfactants preferably nonionic surfactants, anionic surfactants, cationic surfactants (excluding quaternary ammonium salts), and amphoteric surfactants (alkyldiaminoethylglycine hydrochloride and alkylpolyaminoethyl).
  • the surfactants include nonionic surfactants, anionic surfactants, cationic surfactants (excluding quaternary ammonium salts), and amphoteric surfactants (alkyldiaminoethylglycine hydrochloride and alkylpolyaminoethylglycine).
  • Surfactant composition for sterilizing or killing viruses.
  • the nonionic surfactant consists of a group consisting of alkyl glucoside, sucrose fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene fatty acid ester, polyglycerin fatty acid ester, polyethylene glycol fatty acid ester, and polyoxyethylene alkyl ether.
  • ⁇ 15> which is one or more selected polyoxyethylene alkyl ethers, preferably polyoxyethylene lauryl ethers, more preferably polyoxyethylene alkyl ethers having 8 or more and 20 or less alkyl groups constituting the polyoxyethylene alkyl ethers.
  • Skin external preparation composition is one or more selected polyoxyethylene alkyl ethers, preferably polyoxyethylene lauryl ethers, more preferably polyoxyethylene alkyl ethers having 8 or more and 20 or less alkyl groups constituting the polyoxyethylene alkyl ethers.
  • the average number of moles of ethyleneoxy groups added to the polyoxyethylene sorbitan fatty acid ester, polyoxyethylene fatty acid ester, polyglycerin fatty acid ester, polyethylene glycol fatty acid ester, and polyoxyethylene alkyl ether is 3 or more and 20 or less, preferably 3 or more and 15 or less. , More preferably 5 or more and 9 or less, still more preferably 5 or more and 8 or less, the composition for external skin preparation for sterilization or virus killing of ⁇ 16>.
  • bactericidal or virus-killing virus of any one of ⁇ 15> to ⁇ 17>, wherein the HLB value of the nonionic surfactant is 8 or more and 16 or less, preferably 10 or more and 14 or less, and more preferably 10 or more and 13 or less.
  • the anionic surfactant is at least one selected from the group consisting of an alkyl sulfate ester salt, an alkyl phosphate ester salt, a polyoxyethylene alkyl ether sulfate ester salt, and a polyoxyethylene alkyl ether phosphate.
  • the content of the surfactant in the external preparation composition for skin is preferably 0.01% by mass or more and 10% by mass or less, more preferably 0.05% by mass or more and 5% by mass or less, still more preferably 0.1% by mass. % Or more and 3% by mass or less, more preferably 0.3% by mass or more and 2% by mass or less, the composition for external skin preparation for sterilization or virus killing according to any one of ⁇ 14> to ⁇ 19>.
  • the content of ethanol in the external preparation composition for skin is preferably 70% by mass or less, more preferably 50% by mass or less, still more preferably 30% by mass or less, still more preferably 10% by mass or less, and further.
  • the composition for external skin preparation for sterilization or virus killing according to any one of ⁇ 1> to ⁇ 20> preferably substantially 0% by mass.
  • the content of the polyol in the external preparation composition for skin is preferably 20% by mass or less, more preferably 10% by mass or less, still more preferably 5% by mass or less, still more preferably 3% by mass or less, and further.
  • the ratio of the total content of ethanol, isopropanol, and polyol to the content of water in the skin external preparation composition is preferably 2 or less as the mass ratio [(ethanol + isopropanol + polyol) / water], more preferably. Is 1 or less, more preferably 0.5 or less, still more preferably 0.1 or less, and the composition for external skin preparation for sterilization or virus killing according to any one of ⁇ 1> to ⁇ 22>.
  • a way to protect the skin from bacteria or viruses (A) One or more acids selected from the group consisting of lactic acid, pyruvic acid and urocanic acid or salts thereof, and (B) An acid other than the component (A) having a pKa of 3.0 or more and 5.0 or less, or a salt thereof, Contains, The content of the component (A) is 0.1% by mass or more and 10% by mass or less. The content of the component (B) is 0.1% by mass or more and 10% by mass or less.
  • a method comprising the step of applying a composition having a pH of 3.5 or more and 5.0 or less at 25 ° C. to the skin, preferably fingers.
  • the content of the component (A) in the composition is preferably 0.3% by mass or more and 8.0% by mass or less, more preferably 0.3% by mass or more and 6.0% by mass or less, and further preferably 0. 3% by mass or more and 5.0% by mass or less, more preferably 0.3% by mass or more and 3.0% by mass or less, still more preferably 0.3% by mass or more and 1.5% by mass or less, still more preferably 0.
  • the method of ⁇ 25> which is 0.5% by mass or more and 1.5% by mass or less.
  • ⁇ 27> The method of ⁇ 25> or ⁇ 26>, wherein the content of lactic acid or a salt thereof in the total amount of the component (A) is preferably 80% by mass or more, more preferably 90% by mass or more, and most preferably 100% by mass. .. ⁇ 28>
  • A One or more acids selected from the group consisting of lactic acid, pyruvic acid and urocanic acid or salts thereof, and (B) An acid other than the component (A) having a pKa of 3.0 or more and 5.0 or less, or a salt thereof, Contains, The content of the component (A) is 0.1% by mass or more and 10% by mass or less. The content of the component (B) is 0.1% by mass or more and 10% by mass or less.
  • a leave-on finger external preparation composition having a pH of 3.5 or more and 5.0 or less at 25 ° C.
  • A One or more acids selected from the group consisting of lactic acid, pyruvic acid and urocanic acid or salts thereof, and (B) An acid other than the component (A) having a pKa of 3.0 or more and 5.0 or less, or a salt thereof, Contains,
  • the content of the component (A) is 0.1% by mass or more and 10% by mass or less.
  • the content of the component (B) is 0.1% by mass or more and 10% by mass or less.
  • A One or more acids selected from the group consisting of lactic acid, pyruvic acid and urocanic acid or salts thereof, and (B) An acid other than the component (A) having a pKa of 3.0 or more and 5.0 or less, or a salt thereof, Contains, The content of the component (A) is 0.1% by mass or more and 10% by mass or less. The content of the component (B) is 0.1% by mass or more and 10% by mass or less.
  • An external skin preparation composition for protecting against bacteria or viruses which has a pH of 3.5 or more and 5.0 or less at 25 ° C.
  • A One or more acids selected from the group consisting of lactic acid, pyruvic acid and urocanic acid or salts thereof, and (B) An acid other than the component (A) having a pKa of 3.0 or more and 5.0 or less, or a salt thereof, Contains,
  • the content of the component (A) is 0.1% by mass or more and 10% by mass or less.
  • the content of the component (B) is 0.1% by mass or more and 10% by mass or less.
  • ⁇ 33> (A) One or more acids selected from the group consisting of lactic acid, pyruvic acid and urocanic acid or salts thereof, and (B) An acid other than the component (A) having a pKa of 3.0 or more and 5.0 or less, or a salt thereof, Contains, The content of the component (A) is 0.1% by mass or more and 10% by mass or less. The content of the component (B) is 0.1% by mass or more and 10% by mass or less.
  • An external skin composition for protecting fingers having a pH of 3.5 or more and 5.0 or less at 25 ° C.
  • PH The pH of the composition was measured at 25 ° C. with an electrode 6637-10D (manufactured by HORIBA, Ltd.). The pH of the skin surface (palm) was measured with an electrode Skin-pH-Meter PH905 (Courage + Khazaka).
  • the molar ratio [acid type / (acid type + dissociation type)] of each component is obtained.
  • the molar ratio [acid type / (acid type + dissociation type)] of each component is obtained.
  • the molar ratio [acid type] of the component (A) when a plurality of types of components (A) are used. / (Acid type + dissociation type)] can be obtained.
  • a bacterial solution of Escherichia coli, Enterococcus, or Serratia prepared by the following method was used.
  • NBRC3301 strain was used as Escherichia coli
  • NBRC3181 strain was used as enterococcus
  • NBRC12648 strain was used as Serratia bacterium.
  • the pH of the skin surface at the site where the composition was applied was measured by the above method, and from this pH value, lactic acid with respect to the total amount of lactic acid and lactic acid ions on the skin surface after the composition was applied by the above formula. [Lactic acid / (lactic acid + lactic acid ion)] was determined. Then, the bacterial solution of Escherichia coli or enterococcus prepared by the above method was uniformly applied to the site where the composition was applied on the palm in a fixed amount (3 ⁇ L / 3 cm 2 ).
  • the bacterial solution applied using two swabs is collected, and the viable bacterial count is measured by the following method using an incubation leader "HiTS” (manufactured by Sinix Co., Ltd.) to determine the bacterial count. The amount of decrease (number of surviving bacteria / initial number of viable bacteria) was confirmed. [Measurement of decrease in bacterial count]
  • the collected bacterial solution was liquid-cultured at 37 ° C. in an incubation leader "HiTS", and the absorbance (turbidity) at a wavelength of 600 nm was measured over time to create a growth curve of the viable cell count in the bacterial solution.
  • the bacterial solution having a known viable cell count was serially diluted, and the culture and growth curve were similarly prepared to prepare a calibration curve between the time to reach a certain turbidity and the viable cell count. From this calibration curve, the number of surviving bacteria in the collected bacterial solution was estimated, and the decrease in the number of bacteria was confirmed.
  • the degree of decrease in the number of bacteria is shown in Table 1 by taking the -log value of the amount of decrease in the number of bacteria. The higher the value of "-log" for Escherichia coli or enterococci, the higher the bactericidal activity.
  • the pH of the skin surface at the site where the composition was applied was measured by the above method, and from this pH value, lactic acid with respect to the total amount of lactic acid and lactic acid ions on the skin surface after the composition was applied by the above formula. [Lactic acid / (lactic acid + lactic acid ion)] was determined. Then, the bacterial solution of Serratia marcescens prepared by the above method was uniformly applied to the site where the composition was applied on the palm in a fixed amount (1 ⁇ L / cm 2 ).
  • the applied bacterial solution was collected using two swabs, and the number of surviving bacteria was measured by the same method as described above using an incubation leader "HiTS" (manufactured by Sinix Co., Ltd.). The amount of decrease in the number of bacteria (surviving number / initial viable number) was confirmed.
  • the degree of decrease in the number of bacteria is shown in Table 1 by taking the -log value of the amount of decrease in the number of bacteria. The larger this value is, the higher the bactericidal property is.
  • Examples 1 to 12 and Comparative Examples 1 to 5 (preparation and evaluation of a composition for external use of fingers) After blending each component in the amounts shown in Table 1 and mixing at room temperature, a hydrochloric acid aqueous solution having a concentration of 1 mol / L and / or an aqueous sodium hydroxide solution having a concentration of 1 mol / L was used as a pH adjuster except for Comparative Example 1. The pH was adjusted to 4.0 to prepare a finger external preparation composition.
  • the blending amount shown in the table is the amount of the active ingredient (% by mass) of each component except for sodium dihydrogen phosphate.
  • the compounding amount in terms of phosphoric acid is shown in Table 1.
  • the pKa described in the table is the pKa of the acid in the component (B).
  • Various evaluations were carried out by the above method using the obtained composition. The results are shown in Table 1.
  • Lactic acid Lactate (active: 90%) Made by Fujifilm Wako Junyaku Co., Ltd.
  • Succinic acid Succinic acid Made by Fujifilm Wako Junyaku Co., Ltd.
  • Ascorbic acid Ascorbic acid Made by Fujifilm Wako Junyaku Co., Ltd.
  • Apple acid Apple Acid Fujifilm Wako Junyaku Co., Ltd.
  • Citric acid Citric acid Fujifilm Wako Junyaku Co., Ltd.
  • Adipic acid Adipic acid Fujifilm Wako Junyaku Co., Ltd.
  • Sodium dihydrogen phosphate Anhydrous sodium dihydrogen phosphate FUJIFILM Wako Junyaku Co., Ltd.
  • the composition of this example has a higher skin bactericidal effect than the composition of the comparative example. It is considered that this is because the pH of the skin surface is kept in the range of about 4.6 or less, and the ratio of the acid type component (A), which is the main bactericidal component, present on the skin surface is high. Further, in the comparison between Comparative Example 1 and Comparative Example 5, the bactericidal effect was hardly enhanced even if benzalkonium chloride was contained, whereas in the comparison between Example 2 and Example 12, the composition of the present invention was used. It can be seen that the bactericidal effect is significantly enhanced by containing benzalkonium chloride. This is considered to be based on the following reasons.
  • composition containing benzalkonium chloride and adjusted to pH 4.0 with hydrochloric acid has a bactericidal effect equivalent to that of pure water. This is because the composition of Comparative Example 5 does not have the ability to buffer the skin pH, the skin pH rises after application, and the surface charge of the skin tilts negatively, so that cationic benzalkonium chloride is applied to the skin. This is because the bactericidal effect of benzalkonium chloride is suppressed by facilitating adsorption.
  • the skin pH is maintained at around pH 4 by the buffering capacity of the components (A) and (B), so that the skin can be treated. It is possible to suppress the negative inclination of the surface charge, and as a result, suppress the adsorption of benzalkonium chloride on the skin, and exert the bactericidal effect of benzalkonium chloride. As a result, the bactericidal effect of the composition of the present invention can be enhanced by containing benzalkonium chloride in combination with the bactericidal effect of the components (A) and (B).
  • Example 1 Comparative Example 2 and Comparative Example 3 all have a pH of 4.0, but the pH behavior on the fingers to which the composition is applied is different. It can be seen that the initial pH of the fingers to which the composition of Example 1 is applied is also low, and the pH is maintained in a relatively low range even after a long period of time.
  • Comparative Example 1 deionized water
  • the initial pH is lower than that of the case and the case of using Comparative Example 2 (deionized water adjusted to pH 4.0), but the pH is increased with the passage of time. Even when an aqueous hydrochloric acid solution having a pH of 1.5 is used, the initial pH decreases to the same level as that of the composition of Example 1, but the pH increases significantly with the passage of time.
  • composition of the present invention the formulations shown in Table 2 can be prepared by conventional methods.
  • Lactic acid Lactic acid (active: 90%) Made by Fujifilm Wako Pure Chemical Industries, Ltd.
  • Succinic acid Succinic acid Made by Fujifilm Wako Pure Chemical Industries, Ltd.
  • Polyoxyethylene EO average number of moles added 6
  • Lauryl ether Emargen 108 Kao ( Made by HLB 12.1 Polyoxyethylene (Average number of moles added by EO: 9)
  • Lauryl ether Emargen 109P, manufactured by Kao Corporation, HLB13.6
  • Sodium hydroxide NaOH (sodium hydroxide aqueous solution) 48% Kanto Chemical Co., Ltd. was used after adjusting to a 1 mol / L aqueous solution of sodium hydroxide.
  • an external skin preparation composition for bactericidal or virus-killing which has a good bactericidal or virus-killing effect and its sustainability, is less irritating to the skin, and is highly safe for the human body. ..

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Une composition dermatologique externe pour une utilisation germicide et virucide selon la présente invention contient (A) un ou plusieurs acides choisis dans le groupe constitué par l'acide lactique, l'acide pyruvique et l'acide urocanique, ou un sel de celui-ci, et (B) un acide autre que le composant (A) qui a un pKa de 3,0 à 5,0, ou un sel de celui-ci, la teneur en composant (A) étant de 0,1 à 10 % en masse et la teneur en composant (B) étant de 0,1 à 10 % en masse, et la composition ayant un pH de 3,5 à 5,0.
PCT/JP2021/020609 2020-06-05 2021-05-31 Composition dermatologique externe pour une utilisation germicide et virucide Ceased WO2021246352A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020-098762 2020-06-05
JP2020098762 2020-06-05

Publications (1)

Publication Number Publication Date
WO2021246352A1 true WO2021246352A1 (fr) 2021-12-09

Family

ID=78830304

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/020609 Ceased WO2021246352A1 (fr) 2020-06-05 2021-05-31 Composition dermatologique externe pour une utilisation germicide et virucide

Country Status (3)

Country Link
JP (1) JP7763601B2 (fr)
TW (1) TW202145995A (fr)
WO (1) WO2021246352A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023032493A1 (fr) * 2021-09-06 2023-03-09 花王株式会社 Préparation cutanée externe

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024075507A (ja) * 2022-11-22 2024-06-03 株式会社ニイタカ 抗ウイルスコーティング剤

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06508612A (ja) * 1991-06-04 1994-09-29 エコラブ・インコーポレイテッド 混合カルボン酸衛生剤
JPH11335696A (ja) * 1998-05-28 1999-12-07 Fuso Chemical Co Ltd 除菌洗浄剤
JP2002501541A (ja) * 1997-06-04 2002-01-15 ザ、プロクター、エンド、ギャンブル、カンパニー リーブオン抗菌組成物
JP2012532141A (ja) * 2009-06-30 2012-12-13 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 植物性成分を含有する抗微生物／防腐組成物
JP2014111575A (ja) * 2012-11-02 2014-06-19 Rohto Pharmaceut Co Ltd 外用組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2781668B1 (fr) * 1998-07-31 2001-06-01 Oreal Procede de traitement de la peau et patch pour la mise en oeuvre du procede
US7147873B2 (en) 2002-01-16 2006-12-12 3M Innovative Properties Company Antiseptic compositions and methods
WO2008111429A1 (fr) 2007-03-09 2008-09-18 Maruishi Pharmaceutical Co., Ltd. Désinfectant
EP3393243B1 (fr) 2015-12-22 2022-03-02 The Procter & Gamble Company Compositions comprenant un amide
JP2018184371A (ja) 2017-04-26 2018-11-22 Ｍｃフードスペシャリティーズ株式会社 ピコルナウイルス科ウイルスの防除方法
JP2019026592A (ja) 2017-07-28 2019-02-21 イーダ株式会社 アルコール系消毒剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06508612A (ja) * 1991-06-04 1994-09-29 エコラブ・インコーポレイテッド 混合カルボン酸衛生剤
JP2002501541A (ja) * 1997-06-04 2002-01-15 ザ、プロクター、エンド、ギャンブル、カンパニー リーブオン抗菌組成物
JPH11335696A (ja) * 1998-05-28 1999-12-07 Fuso Chemical Co Ltd 除菌洗浄剤
JP2012532141A (ja) * 2009-06-30 2012-12-13 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 植物性成分を含有する抗微生物／防腐組成物
JP2014111575A (ja) * 2012-11-02 2014-06-19 Rohto Pharmaceut Co Ltd 外用組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023032493A1 (fr) * 2021-09-06 2023-03-09 花王株式会社 Préparation cutanée externe

Also Published As

Publication number Publication date
JP7763601B2 (ja) 2025-11-04
TW202145995A (zh) 2021-12-16
JP2021193078A (ja) 2021-12-23

Similar Documents

Publication Publication Date Title
US11044914B2 (en) Antimicrobial sanitizer compositions and their use
EP2424352B1 (fr) Procédés et composition de traitement d'un matériau
US7592300B2 (en) Antimicrobial compositions containing an aromatic carboxylic acid and a hydric solvent
AU2023203406B2 (en) Emollient topical disinfectants
JP7023949B2 (ja) 洗濯物洗浄工程で使用するための殺生物性組成物
CN101646342A (zh) 消毒剂
EP0938542A1 (fr) Composition de nettoyage desinfectante aqueuse
JP2017505324A (ja) 胞子及び他の生物に対する効力を有する組成物及び方法
US20140011766A1 (en) Antimicrobial compositions and methods
US20090232748A1 (en) Virucidal activities of cetylpyridinium chloride
RU2151614C1 (ru) Антимикробная композиция и способ стерилизации
US9833471B1 (en) Hypochlorous acid-based hand sanitizer
WO2021246352A1 (fr) Composition dermatologique externe pour une utilisation germicide et virucide
US20050100601A1 (en) Virucidal activities of cetylpyridinium chloride
EP1686993A2 (fr) Activites virocides du chlorure de cetylpyridinium
US6015530A (en) General applicable topical germicide
CN116096368B (zh) 免洗型皮肤外用剂组合物
US20020136768A1 (en) Antimicrobial composition
JP2777148B2 (ja) 少なくとも１種の単細胞生物を阻害し，又は破壊する，弗素Ｆ▲上−▼及びリチウムＬｉ▲上＋▼を含む組成物
JP7754617B2 (ja) 殺菌又は殺ウイルス性組成物
JP2023017494A (ja) 皮膚を菌又はウイルスから防御する方法
JP2023017691A (ja) 容器詰液状組成物
CN118252760A (zh) 一种消毒杀菌湿巾及其制备方法
JP2025009169A (ja) 皮膚用アルコール消毒剤組成物
JP2024083006A (ja) リーブオン液状殺菌剤組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21817514

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21817514

Country of ref document: EP

Kind code of ref document: A1